Skip to main content
Premium Trial:

Request an Annual Quote

Lion Cinches NetGenics Acquisition

NEW YORK, Jan. 31 - Lion Bioscience has tied up its acquisition of NetGenics, the company said on Wednesday.

The acquisition, first announced two weeks ago, makes NetGenics a part of Lion's US-based operations.


Manuel Glynias, NetGenics' president and CEO, will become senior vice president for strategic planning at Lion, and Michael Dickson, who was chief technology officer at NetGenics, will become a the senior principal architect at Lion. Both men "will initially focus on the integration of NetGenics' DiscoveryCenter software" into Lion's product portfolio, Lion said in a statement.


A spokeswoman for Lion's US headquarters, in Cambridge, Mass., said that the rest of NetGenics' employees will be spared their jobs.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.